Baker IDI Heart &； Diabetes Institute Holdings Ltd.;Universitaetsklinikum Freiburg
发明人:
Andreas ZIRLIK,Dennis WOLF,Karlheinz PETER
申请号：
US16702692
公开号：
US20200093924A1
申请日:
2019.12.04
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
